Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles

Bayer Diabetes Care Launches A1CNow(R) SELFCHECK, A New A1C Monitor For At-Home Use
Bayer Diabetes Care announced the launch of A1CNow(R) SELFCHECK, a new A1C monitor that enables people with diabetes to check their A1C level at home. Measurement of A1C provides an average assessment of blood sugar levels over the past three months -- and is an indicator of how well diabetes is being managed. The U.S. Food and Drug Administration recently cleared Bayer"s A1CNow SELFCHECK which enables patients to more closely watch their A1C level in between healthcare provider visits so they may modify their diet and exercise, or have a more informed discussion with their healthcare provider based on the results.

Nip The Problem In The Bud - Nay The Leaf
Tobacco is the only consumer product which is grown and available legally and is lethal for human beings. At the current rate, the number of smokers dying every year in the world is likely to reach (10 million) 1 crore by 2020.
News of the day
Secrets Revealed About How Disease-Causing DNA Mutations Occur
A team of Penn State scientists has shed light on the processes that lead to certain human DNA mutations that are implicated in hundreds of inherited diseases such as tuberous sclerosis and neurofibromatosis type 1. The results one day could influence the way couples who seek to have children receive genetic counseling. The team, led by Kateryna Makova, an associate professor of biology, also includes Erika Kvikstad, a graduate student in the Department of Biology, and Francesca Chiaromonte, an associate professor of statistics. Their findings will be published in the July 2009 issue of the journal Genome Research.
Sexual Health

New Research Claims Cholesterol Drug Could Reduce Risk Of Amputations In People With Diabetes

People with diabetes who were prescribed the cholesterol-lowering drug fenofibrate reduced their risk of minor amputations by 36 per cent, according to new research. Researchers in Australia, Finland and New Zealand looked at almost 10,000 people aged between 50 and 75 with Type 2 diabetes. About half of them were given fenofibrate while the other half were given placebos. New discovery The study, first published in 2005, aimed to see if fenofibrate prevented heart disease, which it did not. But in this new analysis, experts found patients on fenofibrate had a 36 per cent lower risk of a first amputation than those on the placebo. The risk of minor amputations in people without large vessel arterial disease was nearly 50 per cent lower in the group taking fenofibrates, but the risk of a major amputation was not substantially different between the two groups. Taller people were also more likely to have amputations. Fenofibrates can cause side effects including abdominal pain, nausea, pancreas and lung problems. Leading research forward "This large trial suggests that the drug fenofibrate could play a role in the reduction of below-the-ankle amputations in people with Type 2 diabetes," said Dr Victoria King, Research Manager at Diabetes UK. "We know that approximately 100 people a week in the UK lose a toe, foot or lower limb due to diabetes. "Managing blood glucose levels by keeping them within acceptable limits can cut the risk of diabetes-related amputations, and trials like this one guide us towards further ways of reducing the risk of diabetes associated amputations." Diabetes UK


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009